We are shaping the future of medicine from the Ruhr region to Ostwestfalen-Lippe.
University Medical Center Bochum, which consists of the Faculty of Medicine and eight supporting clinics, supported by numerous teaching hospitals, we combine practical teaching, innovative research and the direct application of our findings in clinical practice. Together, we are working on the cutting-edge medicine of tomorrow - for committed students, a sustainable society and strong healthcare provision throughout the region.
The curriculum of our integrated reform medicine (iRM) degree program places particular emphasis on interdisciplinarity and practical relevance. This flexible and future-oriented education optimally prepares our students for the medical challenges of tomorrow.
Our research excels in basic research, translational science, and clinical studies, with a focus on protein sciences, oncology, and neuroscience. Following the 'From Bench to Bedside' approach, we translate laboratory findings directly into clinical applications, setting global standards.
Through the diversity of our partner hospitals and academic teaching hospitals, we position ourselves strongly in clinical education, research, and patient care. This close collaboration makes us one of the largest and most efficient university hospitals in Germany, ensuring excellent training and top-quality patient care.
PD Dr Felix Kleefeld has received the 2026 Felix Jerusalem Prize for his research into inclusion body myositis. His findings reveal early mitochondrial damage and could open new avenues for treatment.
Researchers from Bochum have discovered why mice are resistant to hepatitis E virus infection: The key barrier occurs when the virus enters cells, providing new insights into how viruses adapt to different host species.
A research project led by Dr. Christina Scheel explores how melanoma cells evade the immune system and why immunotherapies fail in some patients. The aim is to develop a test that better predicts treatment response and supports more individualized therapy decisions.
The biomarker p-tau217 is considered promising for early Alzheimer’s detection but shows surprisingly weak performance in preclinical stages. The study led by Prof. Dr. Gerwert challenges current assumptions and may influence the development of future diagnostic approaches.